Loading patent…
AssigneesBurnham Institue for Medical Research, The Regents of the Universtiy of California
InventorsDouglas Hanahan, Erkki Ruoslahti, Johanna A. Joyce, Pirjo Laakkonen
Estimating the term…
The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
An isolated peptide having a length of less than 60 amino acid residues and comprising the amino acid sequence selected from CRGRRST (SEQ ID NO:5), CRSRKG (SEQ ID NO:9), and CKAAKNK (SEQ ID NO:15), wherein said peptide selectively homes to premalignant pancreatic vasculature, malignant pancreatic vasculature or pancreatic tumor cells.
A conjugate, comprising a therapeutic moiety linked to a peptide that selectively homes to vasculature of premalignant pancreas, said peptide comprising the amino acid sequence CRSRKG (SEQ ID NO:9);
A conjugate, comprising a therapeutic moiety linked to a peptide that selectively homes to vasculature of premalignant pancreas, wherein said peptide binds specifically to a cognate receptor for SEQ ID NO:9, wherein said peptide has a length of less than 100 residues.
A conjugate, comprising a therapeutic moiety linked to a peptide that selectively homes to pancreatic tumor cells or pancreatic tumor vasculature, said peptide comprising the amino acid sequence CKAAKNK (SEQ ID NO:15), wherein said peptide has a length of less than 100 residues.
A conjugate, comprising a therapeutic moiety linked to a peptide that selectively homes to pancreatic tumor cells or pancreatic tumor vasculature, wherein said peptide binds specifically to a cognate receptor for SEQ ID NO:15, wherein said peptide has a length of less than 100 residues.
A conjugate, comprising a therapeutic moiety linked to a peptide that selectively homes to premalignant or malignant pancreatic vasculature, said peptide comprising the amino acid sequence CRGRRST (SEQ ID NO:5), wherein said peptide has a length of less than 100 residues.
A conjugate, comprising a therapeutic moiety linked to a peptide that selectively homes to premalignant or malignant pancreatic vasculature, wherein said peptide binds specifically to a cognate receptor for SEQ ID NO:5, wherein said peptide has a length of less than 100 residues.
A multivalent conjugate, comprising a therapeutic moiety linked to at least two peptides that selectively home to vasculature of premalignant pancreas, each of said peptides comprising the amino acid sequence CRSRKG (SEQ ID NO:9).
A multivalent conjugate, comprising a therapeutic moiety linked to at least two peptides that selectively home to vasculature of premalignant pancreas, wherein each of said peptides binds specifically to a cognate receptor for SEQ ID NO:9.
A multivalent conjugate, comprising a therapeutic moiety linked to at least two peptides that selectively home to pancreatic tumor cells or pancreatic tumor vasculature, each of said peptides comprising the amino acid sequence CKAAKNK (SEQ ID NO:15).
A multivalent conjugate, comprising a therapeutic moiety linked to at least two peptides that selectively home to premalignant or malignant pancreatic vasculature, wherein each of said peptides binds specifically to a cognate receptor for the amino acid sequence CKAAKNK (SEQ ID NO:15).
A multivalent conjugate, comprising a therapeutic moiety linked to at least two peptides that selectively home to premalignant or malignant vasculature, each of said peptides comprising the amino acid sequence CRGRRST (SEQ ID NO:5).
A multivalent conjugate, comprising a therapeutic moiety linked to at least two peptides that selectively home to pancreatic tumor cells or pancreatic tumor vasculature, wherein each of said peptides binds specifically to a cognate receptor for the amino acid sequence CRGRRST (SEQ ID NO:5).
Dependencies are inferred from the claim text.